Page 12 - Business Developments News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Gaby Inc. Reports Q1 2021 Revenue of $3.4MM and Record First Quarter 2021 Pro Forma Revenue of $12.3MM ACCESSWIRE Record Q1 pro forma revenue i of $12.3 MM up 8.5x over Q1 2020 revenue Revenue of $3.4MM up 135% over same quarter last year Record Q1 pro forma EBITDA i of $1MM up 140% over Q1 2020 EBITDA i SANTA ROSA, CA / ACCESSWIRE / May 26, 2021 / GABY Inc. (' GABY' or the ' Company') (CSE:GABY)(OTCQB:GABLF), a cannabis retail consolidator operating exclusively in California is pleased to announce first quarter revenue was $3.4 million, up 135% from the same quarter last year and its Q1 2021...

Employee spotlight - Emma Parr Emma Parr joined Crawford in Febuary 2020 as Head of Key Clients and was recently promoted to Chief Client Officer, UK & Ireland. Crawford's clients are its lifeblood and Emma's appointment demonstrates Crawford's commitment to being a client-centric business dedicated to helping clients and their customers when they need it most. One of Emma's standout achievements of the past year was contributing to the roll-out of Crawford's Business Interruption Portal, a digital solution that has helped the insurance market cope with the massive uptick in COVID-related BI ...

Message : Required fields Emma Parr joined Crawford in Febuary 2020 as Head of Key Clients and was recently promoted to Chief Client Officer, UK & Ireland. Crawford's clients are its lifeblood and Emma's appointment demonstrates Crawford's commitment to being a client-centric business dedicated to helping clients and their customers when they need it most. One of Emma's standout achievements of the past year was contributing to the roll-out of Crawford's Business Interruption Portal, a digital solution that has helped the insurance market cope with the massive uptick in COVID-rela...

Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results May 03, 2021 08:00 ET | Source: Rhythm Pharmaceuticals, Inc. Rhythm Pharmaceuticals, Inc. -- First U.S. commercial sales of IMCIVREE™ (setmelanotide) completed late in first quarter – -- Late-breaking data presentations at ENDO 2021 demonstrated continued weight loss with setmelanotide at up to nine months in HET obesity, as well as weight loss data in adults and BMI-Z reductions in adolescents with Bardet-Biedl syndrome -- -- Delivered proof-of-concept data from Phase 2 Basket Study in HET POMC, ...

FBD building, Bluebell, Co Dublin. Last week, the High Court ruled against FBD Insurance in a landmark case taken by four publicans over FBD’s interpretation of its business interruption cover. The High Court ruling stated that FBD must pay insurance on claims made by publicans relating to the forced closure of their premises due to COVID-19 restrictions. The court also ruled that publicans can base their insurance claims on normal business levels, and not on the reduced level of trade caused by COVID-19 as argued by FBD. Publicans In short, FBD lost its High Court argument on all the ma...